Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.49 |
| ▸ | MAOA | P21397 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979146 | 0.89 | ESR1 (0.52) | MAOA | |
| SCHEMBL14159973 | 0.78 | IKBKB (0.33) | — | |
| SCHEMBL721964 | 0.75 | MAOB (0.65) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL9540720 | 0.75 | F2 (0.57) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL1576877 | 0.75 | NPC1 (0.63) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL30026512 | 0.75 | NPC1 (0.63) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL9568686 | 0.72 | MAOB (0.50) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL22803696 | 0.72 | NPC1 (0.67) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL24706318 | 0.71 | CYP3A4 (0.55) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL22803844 | 0.70 | ESR1 (0.61) | MAOBMAOANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133203-B2 | Pyrroloquinazoline compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133203-B2 | Pyrroloquinazoline compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140378486-A1 | PYRROLOQUINAZOLINE COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378486-A1 | PYRROLOQUINAZOLINE COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2014205272-A1 | PYRROLOQUINAZOLINE COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378486-A1 | PYRROLOQUINAZOLINE COMPOUNDS | COQ8A, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAOB 658/4885MAOA 556/4885NPC1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.